Mayo, AVIA announce innovation challenge finalists

Mayo Clinic and AVIA, a Chicago-based provider-led accelerator, have announced the six finalists who will be competing in Mayo's inaugural THINK BIG Challenge.

The challenge focused on two key categories: Got Health, promoting health maintenance and prevention, and I Am Not My Disease, helping people with chronic illnesses live productive lives.

Selected finalists will compete on Oct. 1 during Transform 2015 for one of two $50,000 awards. 

The six finalists are:

Got Health

1. Care at Hand: Provides evidence-based surveys and analytics platform to predict and prevent hospitalizations

2. Datu Health: Offers a digital platform to engage consumers in their daily health with the ultimate goal of changing unhealthy behaviors

3. Seiva Technologies: Develops clothing with embedded sensors and electronics, which collect data to analyze

I Am Not My Disease

1. Livongo: Combines technology, real-time information and human support to assist people living with chronic conditions

2. physIQ: Remote monitoring solution to use continuous vital sign data as an early warning system for heart failure and respiratory exacerbation

3. Wellpepper: A platform for digital treatment plans that allows health systems to embed their own care pathways and collect patient-reported information

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.